Lp(a) lipoprotein purified from human plasma bound with high affinity to isolated bovine LDL receptors on nitrocellulose blots and in a solid-phase assay. Lp(a) also competed with 125I-LDL for binding to human LDL receptors in intact fibroblasts. Binding led to cellular uptake of Lp(a) with subsequent stimulation of cholesterol esterification. After intravenous injection, human Lp(a) was cleared slowly from the plasma of normal mice. The clearance was markedly accelerated in transgenic mice that expressed large amounts of LDL receptors. We conclude that the covalent attachment of apo(a) to apo B-100 in Lp(a) does not interfere markedly with the ability of apo B-100 to bind to the LDL receptor and that this receptor has the potential to play a major role in clearance of Lp(a) from the circulation of intact humans. (J. Clin. Invest
Introduction
Lp(a), a lipoprotein particle found in the plasma of higher primates and many humans, is an important predisposing factor to atherosclerosis (reviewed in reference 1). The major component of Lp(a) is a LDL particle, which contains a single protein of -550 kD, designated apoprotein (apo)l B-100. Lp(a) differs from LDL in containing an additional protein, designated apo(a), that is attached to apo B-100 in disulfide linkage. Apo(a) is related structurally to plasminogen, a circulating serine protease that is activated during clot lysis (2, 3) . Plasminogen, like several other proteases of the blood clotting system, contains several cysteine-rich sequences called kringles. Apo(a) contains 37 or more copies of one particular kringle, namely kringle 4, followed by a single copy of kringle 5 and a protease domain (2) . At least six different alleles exist at the apo(a) locus in humans, and these produce apo(a) proteins that vary in molecular weight from -400,000 to 700,000 (4) . This size variation is apparently attributable to different num-Receivedfor publication 21 November 1989.
1. Abbreviations used in this paper: apo, apoprotein; FH, familial hypercholesterolemia; IDL, intermediate density lipoprotein. bers of copies of kringle 4 (1) . There are also apparent null alleles that produce no detectable circulating protein (1) .
In Caucasian populations, the distribution of Lp(a) concentrations in plasma is highly skewed. Most subjects have Lp(a) concentrations below 30 mg/dl, but a substantial minority have concentrations extending up to 100 mg/dl (1) . The latter individuals are at greatly increased risk for coronary artery disease. Part of the variation in Lp(a) concentrations is attributable to the allele at the apo(a) locus. In general, the smaller apo(a) proteins are present at higher levels in plasma. Substantial variability in Lp(a) levels exists even among individuals who produce the same size apo(a) protein. One reason for this variation relates to allelic differences at the LDL receptor locus. Individuals with familial hypercholesterolemia (FH), who have one defective LDL receptor gene, have a twoto three-fold elevation in plasma Lp(a) levels when compared with other individuals who have the same genotype at the apo(a) locus (5) . These findings suggest that Lp(a), like LDL, is removed from plasma by binding to LDL receptors.
Several studies of Lp(a) binding and metabolism in cultured human fibroblasts have suggested that the lipoprotein binds to LDL receptors, but conflicting data have appeared. Maartmann-Moe and Berg (6) originally presented evidence that Lp(a) bound poorly, if at all, to LDL receptors. Floren et al. (7) , in contrast, showed that Lp(a) stimulated the synthesis ofcholesteryl esters in normal human fibroblasts, an event that requires receptor-mediated endocytosis of the lipoprotein. Lp(a) had much less effect on fibroblasts from a patient with homozygous FH, strongly suggesting that LDL receptors were involved. Havekes et al. (8) also provided evidence that Lp(a) binds to LDL receptors in human fibroblasts. Armstrong et al. (9) , on the other hand, found that Lp(a) was not taken up as readily as LDL in fibroblasts and that uptake ofthe lipoprotein was markedly increased when the disulfide bond was reduced, liberating apo(a) and generating active LDL. In the most comprehensive study to date, Krempler et al. (10) showed that '251I-labeled Lp(a) bound to fibroblasts with an affinity that was comparable to that of LDL and that the two lipoproteins showed cross competition. These investigators also showed that the fractional catabolic rate ofintravenously-administered Lp(a) was correlated with the fractional catabolic rate of LDL in intact human subjects.
With the availability of purified LDL receptors (1 1), it is now possible to study the receptor binding of lipoproteins directly. In the current studies, we show that Lp(a) binds to purified LDL receptors in vitro with an affinity similar to that of LDL. We also show that the clearance of human Lp(a) from plasma is markedly elevated in transgenic mice that overproduce human LDL receptors (12) . These data provide strong support for the hypothesis that the LDL receptor plays an important role in the catabolism of Lp(a).
Methods
Materials. We obtained bovine serum albumin (fraction V., No. A4503) from Sigma Chemical Co. (St. Louis, MO); low molecular weight markers from Bio-Rad Laboratories (Richmond, CA); high molecular weight markers from Pharmacia Fine Chemicals (Piscataway, NJ); nitrocellulose (BA85) from Schleicher and Schuell, Inc. (Keene, NH); and rabbit anti-human LDL IgG from Calbiochem-Behring Corp. (San Diego, CA). Goat anti-rabbit IgG and rabbit antimouse IgG were obtained from Cappell Laboratories (Malvern, PA) and radiolabeled with 125I as described (13) . Bovine LDL receptor was purified as described (1 1). Normal mice (C57BL X SJL) were obtained from Jackson Laboratory (Bar Harbor, ME). Homozygous transgenic mice were derived from a previously described strain of mice expressing the human LDL receptor cDNA transgene-under the control ofthe mouse metallothionein-I promoter (line 93-4) (12) .
Preparation oflipoproteins. Human LDL (d 1.019-1.063 g/ml) was prepared from the plasma of healthy subjects by KBr density gradient ultracentrifugation as described ( 14) . LDL was radioiodinated with 125I by the iodine monochloride method (14) . Lp(a) was prepared by two different methods. Lp(a) was isolated from subjects 1 and 2 by ultracentrifugation (d 1.050-1.120 g/ml) followed by Sepharose CL-6B chromatography as described by Ye et al. (15) . The fractions containing Lp(a) had pre-3 mobility on agarose electrophoresis, reacted with anti-Lp(a) and anti-LDL antisera by Ouchterlony double diffusion analysis, and had no contamination with other apo B-containing lipoproteins as shown by double-tier rocket immunoelectrophoresis (15) . Lp(a) from subjects 3, 4, and 5 was prepared by ultracentrifugation and monoclonal antibody affinity chromatography, employing a monoclonal antibody specific for apo(a). Briefly, plasma from subjects with high Lp(a) levels was adjusted to 1 mM each of diisopropylfluorophosphate, EDTA, and sodium azide, and to a density of 1.21 g/ml by the addition of solid NaBr. The plasma was centrifuged at 59,000 rpm for 20 h at 19°C in a 60 Ti rotor (Beckman Instruments, Inc., Palo Alto, CA), and the floating lipoprotein fraction was collected and immediately passed over an Lp(a) monoclonal antibody column (monoclonal 2G7, coupled to glycerol-coated control pore glass [16] ). The column was washed with buffer containing 50 mM Tris-HCl at pH 7.5, 1 M NaCl, 1 mM diisopropylfluorophosphate, 1 mM EDTA, and 1 mM sodium azide, after which the Lp(a) was eluted with 0.1 M glycine-HCI ethyl ester at pH 2.3. Eluted fractions were neutralized by collection into 0.1 vol of 1 M Tris-HCI, pH 7.5. The molecular weights (X l10-) of apo(a) from subjects 1-5, as estimated by SDS-PAGE, were 600, 600, 480, 710, and 770, respectively. Plasma Lp(a) immunoassay. Apo(a)-specific monoclonal antibody 2G7 (16) was bound to microtiter plates by incubation overnight at 4°C with 0.1 ml of 0.8 Ag/ml of monoclonal antibody per well in 15 mM Na2CO3/35 mM NaHCO3 at pH 9.6. The coating solution was removed and 0.15 ml of 0.5% (wt/vol) bovine serum albumin in phosphate-buffered saline was added and incubated 1 h at room temperature. The wells were washed three times with cold phosphate-buffered saline containing 0.05% (vol/vol) Tween 20 and 0.01% (wt/vol) thimerosal at pH 7.4 (wash buffer). An Lp(a) standard was prepared by diluting a stock solution into phosphate-buffered saline containing 0.5% bovine serum albumin, 0.05% Tween 20, and 0.01% thimerosal at pH 7.4 (assay buffer) to give concentrations between 0.5 and 90 ng total protein/ml of Lp(a). Test samples were diluted in assay buffer. Samples were dispensed into the coated wells (100 dL/well) in duplicate. The microtiter plates were sealed and incubated at room temperature for 3 h with gentle agitation. The plates were washed six times with wash buffer, after which horseradish peroxidase-labeled antibody (100 AL/well) was added and incubated 2 h at room temperature (16) .
LDL receptor assays in cell monolayers. TR-7 15-19 cells, a stable line of Chinese hamster ovary cells transfected with a cDNA encoding the human LDL receptor (17) and normal diploid human fibroblasts (14) were grown in monolayer culture as described in the indicated reference. Assays of the cell surface binding of '251-LDL at 4°C (dextran sulfate-releasable fraction) and of lipoprotein-mediated stimula-tion of cholesteryl ["4C]oleate formation at 370C were carried out as previously described (14) .
LDL receptor ligand blotting assay. Purified bovine LDL receptor (1I g) (I 1) was subjected to electrophoresis on 7% SDS polyacrylamide gels under nonreducing conditions and transferred to nitrocellulose filters as previously described (18) . The filters were then incubated in a buffer with either human LDL or Lp(a) at a concentration of 5 or 10 yg of protein/ml, respectively, in a buffer containing 50 mM Tris-HCl at pH 8.0, 1 mM potassium iodide, 2 mM CaCl2, and 50 mg/ml bovine serum albumin (blotting buffer). The binding reaction was carried out for I h at 370C with gentle agitation. The filters were washed twice for 15 min with blotting buffer at room temperature, and an IgG fraction ofa rabbit anti-human LDL polyclonal antibody or ofa mouse monoclonal anti-Lp(a) antibody was added as indicated in the legend to Fig.  2 . Incubations were carried out for I h at room temperature. The filters were washed as above, and 251I-labeled goat anti-rabbit IgG (5 X 106 cpm/ml, 107 cpm/ug) or '251-labeled rabbit anti-mouse IgG (5 X 106 cpm/ml, _ 107 cpm/gg) was incubated with the filters for I h at room temperature. The filters were washed, dried, and exposed to film as indicated in the figure legend.
Solid phase LDL binding assay. Binding of 1251I-LDL to the LDL receptor in the presence of unlabeled LDL or Lp(a) was measured using a solid phase assay as described by van (5 Mg protein/ml) and varying concentrations of unlabeled LDL or Lp(a) were mixed in buffer A, added to the wells, and incubated with gentle agitation for I h at 4°C. The unbound lipoproteins were removed, and the wells were washed four times with buffer A at 4°C and counted in a gamma counter. A parallel set of incubations was performed in the presence of 5 mM EDTA, which specifically disrupts the interaction of LDL and its receptor (1 1). The amount of '25I-LDL bound in the presence of EDTA was subtracted from that bound in the presence of calcium to determine specific binding. Clearance of'22I-LDL and Lp(a) from the plasma ofmice. Homozygous transgenic mice that overexpress the human LDL receptor under control of the mouse metallothionein I promoter (12) and normal mice of the same strain ([C57BL X SJL] Fl hybrids) were treated with CdSO4 (1 mg/kg) intraperitoneally 12 and 6 h before the experiment. Approximately equal numbers of male and female animals 4-6 wk of age were used. The mice were anesthetized with sodium pentobarbital (90 mg/kg intraperitoneally), and each received an intravenous bolus via the external jugular vein of 0.15 ml of 0.15 M NaCl containing bovine serum albumin (2 mg/ml), '251I-LDL, and unlabeled Lp(a), as described in the legend to Fig. 6 . In one experiment, an excess of unlabeled LDL (0.5 mg) was co-injected with the '251I-LDL and Lp(a). Blood was collected by retroorbital puncture and placed in EDTA-coated tubes at the times indicated, and a portion ofthe plasma was counted for its 1251 content. The remainder was frozen and assayed at a later time for its Lp(a) content by a monoclonal-based, enzymelinked immunoassay (see above). All transgenic mice had no detectable mouse apo B in the plasma at time 0; the average apo B level in the normal mice was 39±7.4 (SD) mg/dl at time 0. Apo B levels were determined by rocket immunoelectrophoresis as previously described ( 12) . Table I presents the clinical data on the five subjects from whom plasma Lp(a) was isolated in the current study. The Lp(a) from subjects 1 and 2 was prepared in Oklahoma, using a gel filtration method (15) . Lp(a) from subjects 3, 4, and 5 was prepared in California, using a monoclonal anti-apo(a) affinity column ( 16) . Fig. 1 shows the protein component of Lp(a) from subjects 3, 4, and 5 as visualized by SDS-PAGE. In the absence of reducing agents, all three Lp(a) preparations gave a single protein band (lanes D-F). In the presence of dithiothreitol, all three preparations yielded two bands, one corresponding to apo B-100, and the other corresponding to apo(a) (lanes A-C). The apparent molecular mass of the apo(a) bands ranged from -480 kD in subject 3 to 770 kD in subject 5. The apparent molecular weights of the apo(a) proteins in Lp(a) from subjects 1 and 2 were estimated by SDS gel electrophoresis and immunoblotting (not shown). Fig. 2 shows a ligand blotting experiment designed to test the ability of Lp(a) to bind to the LDL receptor. For this purpose, purified bovine LDL receptor was subjected to SDS gel electrophoresis and blotted onto nitrocellulose sheets, which were then incubated with either LDL or Lp(a). After The dried filters were exposed to Kodak XAR-5 film at room temperature for 2 h (lanes 1-4) or 30 min (lanes 5-8). The Lp(a) used in lanes 3 and 4 was prepared from subject 4 by monoclonal antibody affinity chromatography. The Lp(a) used in lanes 7 and 8 was prepared from subject 2 by Sepharose CL-6B chromatography as described under Methods.
Results
washing, the sheets were stained with an antibody directed against LDL or with a specific antibody against the apo(a) component of Lp(a). We used Lp(a) from two different subjects, number 4 prepared in California (left) and number 2 prepared in Oklahoma (right). Both Lp(a) preparations gave similar results. When the nitrocellulose sheets were incubated with LDL, a labeled band was observed with the antibody against LDL (lanes I and 5), but not with the antibody against Lp(a) (lanes 2 and 6). This finding confirms that the Lp(a) antibody was specific for the apo(a) component of Lp(a). When the nitrocellulose sheets were incubated with Lp(a) and then stained with the Lp(a) antibody, positive immunoreactivity was seen (lanes 3 and 7). A positive result was also observed when these strips were stained with the anti-LDL antibody (lanes 4 and 8). These data indicate that the bovine LDL receptor binds intact Lp(a).
To determine whether the human LDL receptor recognized Lp(a) when present on the surface of intact cells, we measured the ability of unlabeled Lp(a) to compete with 12511 LDL for binding to hamster cells that express high levels ofthe human LDL receptor, owing to transfection with an expressible cDNA. As shown in Fig. 3 , Lp(a) from subjects 1 and 2 was equally as effective as LDL in competing for '251-LDL binding when the data are expressed on the basis of the apo B-100 content of the lipoprotein particle. These findings suggest that the apo B component of these Lp(a) preparations bound to the human LDL receptor with an affinity similar to that of the apo B in native LDL.
To determine whether Lp(a) was capable of delivering its cholesterol to cells through the LDL receptor, we compared the ability of LDL and Lp(a) to stimulate the incorporation of by internalization in coated pits, hydrolysis ofthe lipoprotein's cholesteryl esters in lysosomes, and reesterification of the cholesterol in the cytosol (20) . When compared on the basis of their apo B-100 content, similar concentrations of Lp(a) did not differ in their ability to stimulate the reesterification reaction ( Fig. 4) .
Another available assay to test for lipoprotein binding to LDL receptors employs receptors that have been immobilized in plastic microtiter wells by binding to adsorbed antibodies i ASuboecI B Subjec2 directed against the receptor's COOH-terminal domain (19). Fig. 5 shows that the LDL receptor under these conditions bound '25I-LDL and that unlabeled LDL competed for this binding. Lp(a) from subjects 1 and 2 competed equally as well as LDL when expressed on the basis of apo B-100 content.
Lp(a) from subjects 3 and 4 also competed with '251I-LDL, but the affinities appeared to be somewhat lower than that of native LDL.
To determine whether the LDL receptor is capable of removing Lp(a) from the circulation, we studied the catabolism of Lp(a) in transgenic mice that express large amounts of the human LDL receptor under control of the metallothionein-I promoter (12) . Groups of normal and transgenic animals were co-injected intravenously with '251-LDL and unlabeled Lp(a). After varying times, blood was drawn and examined for its content of '251I-LDL radioactivity and for its concentration of apo(a) as measured with a sensitive radioimmunoassay. In the normal mice, LDL and Lp(a) were removed slowly from the circulation. In the transgenic animals, the removal rate for LDL and Lp(a) were both markedly elevated (A-D). The relative increase in removal rate for Lp(a) was similar to the relative increase in the removal rate for LDL.
Because of the overexpression of the LDL receptor in transgenic animals, plasma from these mice does not contain detectable LDL (12) . To rule out the possibility that the enhanced rate of Lp(a) turnover was attributable to the low concentration of circulating LDL, we performed an additional experiment in which Lp(a) was injected together with a tracer amount of 1251I-LDL and a large amount ofunlabeled LDL that was calculated to raise the animals' LDL levels to values ap- '251I-LDL ( proximating those in the control mice. We also extended the time period for the turnover study to 300 min. As shown in panels E and F, the 1251-LDL and Lp(a) were both cleared much more rapidly from the plasma of transgenic mice as compared with normal mice.
Discussion
In the current experiments, we have used five different assays to demonstrate that intact Lp(a) binds with high affinity to the LDL receptor. The most direct ofthese was the demonstration that Lp(a) binds to the purified receptor on nitrocellulose blots (Fig. 2) . The bound Lp(a) was visualized with an antibody that was specific for the apo(a) component, ruling out the possibility that the binding was attributable to a fraction of Lp(a) that had lost its apo(a). In intact cells, the Lp(a) binding was functional in that it stimulated cholesterol esterification (Fig. 4 ), a finding that agrees with previous data of Floren et al. (7) . To guard against the possibility that the activity ofLp(a) somehow depended on its method of purification, we used Lp(a) prepared in two different laboratories with two different methods, and both gave similar results. The experiments with transgenic mice indicate that the LDL receptor can effectively remove Lp(a) from the circulation ( Fig. 6 ). To make certain that we were observing the removal of intact Lp(a), we followed the Lp(a) by a radioimmunoassay that was specific for apo(a). This maneuver allowed us to avoid any modification of the Lp(a) particle, such as radioiodination or enrichment with radiolabeled lipids.
The current findings, considered together with previous data, would appear to provide a simple explanation for the elevated Lp(a) levels in FH heterozygotes that have been observed by Utermann et al. (5) . If Lp(a) depends upon the LDL receptor for its clearance from plasma, then a reduction in LDL receptors should lead to a corresponding increase in Lp(a) levels, owing to impaired clearance. Several observations argue against such a simple interpretation, however.
First, although a defect in LDL receptors raises Lp(a) levels (5), a mutation in apo B-100 that abolishes receptor binding (21, 22) does not elevate Lp(a) levels (1). Theoretically, ifLp(a) removal is dependent upon apo B-100 binding to LDL receptors, then the apo(a) should accumulate together with its defective apo B-100 in the blood. Second, drugs that increase LDL receptor activity, such as bile acid-binding resins and 3-hydroxy-3-methylglutaryl CoA reductase inhibitors, do not appear to lower Lp(a) levels in plasma (1) . Third, the clearance of Lp(a) from blood was less markedly reduced than the clearance of LDL in one FH homozygote studied by Krempler et al. (10) . Fourth, the variation in Lp(a) levels among individuals appears to be caused by differences in the rate of synthesis of Lp(a) rather than in its rate of degradation (10) . The latter studies were performed before it was realized that the different alleles at the apo(a) locus produce different levels of apo(a) in plasma, owing to differences in production rate (1) .
At present, there is no simple way to reconcile all of these data. What is needed is a comparative study of Lp(a) turnover in individuals with different genotypes at the apo(a) locus and the LDL receptor locus. It will also be necessary to determine carefully whether Lp(a) particles produced by different alleles at the apo(a) locus bind with equal affinity to LDL receptors.
The current study does not include a sufficient number of patients to begin to make any such correlation. If such studies and unlabeled Lp(a) (2-6 ug of total protein), and blood was collected at the indicated times for determination of 1251 content (-, A) by gamma counting and Lp(a) content (o, A) by immunoassay. The "100% of control" values represents the values for plasma 1251 and Lp(a) at 1 min after injection in each animal. The mean and range of values for the indicated number of animals are shown. In E and F, excess unlabeled LDL (0.5 mg protein) was included in the injection mixture for the transgenic mice only. The mean value of plasma apo B in the normal mice was 39±7.4 mg/dl (SD) before injection and 37±9.3 mg/dl at 1 min after injection; the mean value in the transgenic mice was 0 before injection and 30±9.5 mg/dl at I min after injection. The source of Lp(a) in these experiments was as follows: A and B, subject 3; C and D, subject 4; E and F, subject 5. are performed with '25I-labeled Lp(a), it will be necessary to demonstrate that the '251-Lp(a) is biologically active in binding to LDL receptors. Under some conditions, radioiodination might inactivate the binding properties of Lp(a), and this must be avoided. It should be noted that all ofthe studies performed in this paper were done with unlabeled Lp(a). In addition, it will be necessary to learn how Lp(a) is produced. Does the apo(a) protein ever exist on a precursor of LDL such as intermediate density lipoprotein (IDL)? If such Lp(a)-bearing precursors exist, do they retain their customary high affinity for binding to LDL receptors? It will also be cru-cial to determine whether apo(a) is added to LDL in the. liver during secretion, or whether the attachment occurs after very low density lipoprotein has been partially or completely metabolized to IDL and LDL. The latter event occurs in the liver under the influence ofhepatic lipase (23) , and it is possible that the apo(a) is not attached to apo B-100 until this stage of metabolism has been reached. Variations in the rate of IDL lipolysis might therefore modulate Lp(a) levels. Clearly, additional work will be required before our understanding of the relationship between Lp(a) and LDL receptors is complete.
